Body Vision Medical
Revolutionizing Lung Cancer Diagnostics

The reason why lung cancer remains the leading cause of cancer-related deaths worldwide is two-fold. One, systematic screening for lung cancer does not exist, as exemplified by the fact that less than 5 percent of persons in the U.S. identified as highrisk for lung cancer underwent lung cancer screening. Second, even if a suspicious lesion is found through screening or incidental imaging, the ability to definitively diagnose or rule out lung cancer in these patients has been less than optimal. Of the two most prevalent methods for lung lesion biopsy in order to obtain a definitive diagnosis, transthoracic needle aspiration or TTNA is the more common and has a high diagnostic success rate due to the use of CTguidance so that the interventional radiologist can confirm that the biopsy is being taken from the lesion. However, the transthoracic nature of the procedure means that it comes with a fair risk for pneumothorax and limits which tumors are accessible via this approach. Conversely, diagnostic bronchoscopy has become an increasingly common biopsy approach due to its minimallyinvasive nature but, historically, has had a lower success rate, with diagnostic yields typically not exceeding 70% compared to 90% for TTNA.

Body Vision Medical is changing this paradigm with its AI-driven, intraoperative CT imaging platform, LungVision™.

Body Vision Medical was founded to address the limitations of diagnostic bronchoscopy such that this less invasive, inherently safer, and a more accessible approach to lung nodule biopsy that can achieve the same diagnostic success rates as more invasive TTNA. One of the key design requirements for the solution was that it had to enhance the quintuple aim for lung cancer diagnostics—improve patient care, boost provider performance, and enhance patient outcomes while simultaneously lowering the cost of care and increasing the number of patients with access to the technology. The resulting solution, LungVision™, is an AI-powered, intraoperative imaging system that transforms X-ray images from any conventional C-arm into intraoperative CT scans in real-time during the procedure.

“Our system allows surgeons and clinicians to use standard tools they have always been using but enhance their natural and skilled performance to deliver similar outcomes as robots, at a fraction of the price in a platform deployable worldwide,” says David Webster, CEO, Body Vision Medical. “We aim to save lives through the democratization of innovative medical technology. Equal access to medtech will enable lung cancer patients to have their disease detected and treated early so they can return to their lives.”

Body Vision Medical’s solution is critical as the healthcare industry faces challenges from rising costs and the resulting shift towards more health economics and outcomesdriven decision-making. LungVision enables bronchoscopists to see exactly where the lesion is and where their bronchoscope and biopsy tools are relative to the lesion in real-time, providing the critical image guidance they need to accurately navigate to the lesion, biopsy, and, if needed, to make informed clinical decisions during the procedure. This maximizes the likelihood that a sufficient sample of lesional tissue is obtained from which a definitive diagnosis can be achieved, saving the lung patient from the worry of not knowing or potentially undergoing additional procedures in pursuit of a diagnosis.

LungVision by Body Vision Medical provides real-time augmented fluoroscopy (left), AI Tomography intraoperative CT (upper right),and an interactive 3D View (lower right) with any C-arm to maximize the likelihood for a definitive lung cancer diagnosis regardless of bronchoscopy setup

LungVision™ also empowers both clinicians and healthcare institutions to build their practice and program with maximum flexibility. It can serve as a standalone platform that provides both image-guided navigation and real-time intraoperative imaging during the diagnostic bronchoscopy procedure or as an adjunct that augments robotic bronchoscopy platforms with the critical, outcomes-enhancing intraoperative imaging they lack.

Our system allows surgeons and clinicians to use standard tools they have always been using but enhance their natural and skilled performance to deliver similar outcomes as robots, at a fraction of the price in a platform deployable worldwide

LungVision seamlessly integrates into the existing procedural workflow, leverages existing equipment the hospital already has in order to reduce the cost of implementation, and comes at a fraction of the cost of electromagnetic navigation (EMN), robotics, or cone-beam CT (CBCT).

This is very much in line with Body Vision’s ethos of delivering clinically effective and economically sound solutions that help hospitals achieve their goals of providing the best possible care while preserving their financial stability. Body Vision Medical’s recent release of a unique subscription model that allows hospitals to acquire LungVision™ without depleting their capital budgets further increases the accessibility of AI-powered imaging for both healthcare providers and the lung patients they treat.

Body Vision Medical is committed to pushing the boundaries of what is possible in lung cancer diagnostics and is constantly striving to further leverage their expertise in AIpowered imaging to improve patient care worldwide.